DDI & Cirrhosis

Combined impact of drug-drug interaction and cirrhosis

substrate

Start typing the name of a drug or scroll down the list to choose one

CYP metabolism is a minor pathway for the elimination of this drug. No relevant interaction with CYP inhibitors or inducers is expected.
Glucuronidation is a major pathway for the elimination of this drug. No relevant interaction with CYP inhibitors is expected. Some inducers (e.g. rifampicin) may lower its exposure.

substrate

Fraction metabolized by each CYP
Adults
Children
 
Warning!

Inducer

Start typing the name of a drug or scroll down the list to choose one

inducer

Induction potency with respect to each CYP
 
Warning!
OR

Inhibitor

Start typing the name of a drug or scroll down the list to choose one

inhibitor

Inhibition potency with respect to each CYP
 
Warning!
 

AUC ratios

Child-Pugh Class
 
Show AUC ratios' interindividual distribution (5th to 95th percentiles)
 
Reset

Definitions

AUCuCIR* / AUCuCIR
This ratio is useful for adapting the dose of the substrate in a cirrhotic patient in whom an optimal dose had been found but an interacting drug is added to the current treatment.
AUCuCIR* / AUCu
This ratio is useful for adapting the initial dose of the substrate to be given to a cirrhotic patient in whom the interacting drug is already prescribed.